Most cited papers from Anhui Provincial Hospital

Anhui Provincial Hospital

What are the most cited papers from Anhui Provincial Hospital?

The most cited paper from Anhui Provincial Hospital is "Effective treatment of severe COVID-19 patients with tocilizumab" (Xiaoling Xu, Mingfeng Han, Tiantian Li et al., 2020), with 2,800 citations. Next come "Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study" (1,154) and "The role of BCL-2 family proteins in regulating apoptosis and cancer therapy" (1,002).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 211 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Effective treatment of severe COVID-19 patients with tocilizumab Xiaoling Xu, Mingfeng Han, Tiantian Li et al. · Proceedings of the National Academy of Sciences Open access	29 Apr 2020	2,800
2	Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study Zhenggang Ren et al. · The Lancet Oncology	15 Jun 2021	1,154
3	The role of BCL-2 family proteins in regulating apoptosis and cancer therapy Shanna Qian, Zhong Wei, Wanting Yang et al. · Frontiers in Oncology Open access	12 Oct 2022	1,002
4	Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders Hua Jiang, Hongbin He, Yun Chen et al. · The Journal of Experimental Medicine Open access	11 Oct 2017	751
5	Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study Shukui Qin et al. · The Lancet Open access138 authors	24 Jul 2023	729
6	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade Zhaolin Chen, Tianlu Shi, Lei Zhang et al. · Cancer Letters	24 Oct 2015	728
7	Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae Liangfei Xu, Xiaoxi Sun, Xiaoling Ma · Annals of Clinical Microbiology and Antimicrobials ReviewOpen access	29 Mar 2017	698
8	Targeting PCDH20 gene by microRNA-122 confers 5-FU resistance in hepatic carcinoma. Wei Wang, Wen Bin Liu, Da Huang et al. · PubMed Open access	2016	611
9	Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial Zixian Wang et al. · Cancer Cell Open access	Mar 2022	592
10	METTL3 and ALKBH5 oppositely regulate m 6 A modification of TFEB mRNA, which dictates the fate of hypoxia/reoxygenation-treated cardiomyocytes Huiwen Song, Xing Feng, Heng Zhang et al. · Autophagy Open access	17 Mar 2019	554
11	Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial Zhihao Lü et al. · BMJ Open access	19 Apr 2022	508
12	Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer Ying Cheng et al. · JAMA Open access109 authors	27 Sep 2022	497
13	Risk Factors for ERCP-Related Complications: A Prospective Multicenter Study Peng Wang, Zhao‐Shen Li, Feng Liu et al. · The American Journal of Gastroenterology	18 Dec 2008	493
14	Air pollution and chronic airway diseases: what should people know and do? Xuqin Jiang, Xiaodong Mei, Di Feng · PubMed Open access	2016	442
15	Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Jie Wang et al. · The Lancet Oncology	13 May 2022	433
16	Statins: a repurposed drug to fight cancer Wen Jiang, Jin-Wei Hu, Xu-Ran He et al. · Journal of Experimental & Clinical Cancer Research Open access	24 Jul 2021	427
17	The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma Ling‐Long Tang et al. · 癌症：英文版 Open access	26 Oct 2021	424
18	Genome-Wide Association Study in Asian Populations Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus Wanling Yang et al. · PLoS Genetics Open access	11 Feb 2010	409
19	Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer Jianming Xu et al. · JAMA Open access	5 Dec 2023	404
20	Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11) Yunpeng Yang et al. · Journal of Thoracic Oncology Open access	8 Aug 2020	404
21	Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling Yuanbo Wu, Meiqiao Chen, Jielong Jiang · Mitochondrion	6 Jul 2019	400
22	Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath Benjie Shan et al. · ACS Nano Open access	18 Aug 2020	386
23	Weight Loss and Malnutrition in Patients with Parkinson's Disease: Current Knowledge and Future Prospects Kai Ma, Nian Xiong, Yan Shen et al. · Frontiers in Aging Neuroscience Open access	18 Jan 2018	382
24	Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer Shun Lü et al. · JAMA Open access	16 Jan 2024	380
25	Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma Lu Jiang et al. · Nature Genetics	20 Jul 2015	380
26	Vitamin D alleviates lipopolysaccharide-induced acute lung injury via regulation of the renin-angiotensin system Jun Mei Xu, Jialai Yang, Jian Chen et al. · Molecular Medicine Reports Open access	May 2017	366
27	2020 Chinese guidelines for ultrasound malignancy risk stratification of thyroid nodules: the C-TIRADS Jianqiao Zhou et al. · Endocrine 239 authors	21 Aug 2020	348
28	Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study Jianming Xu et al. · The Lancet Oncology	17 Apr 2023	339
29	Addiction related alteration in resting-state brain connectivity Ning Ma, Ying Liu, Nan Li et al. · NeuroImage Open access	27 Aug 2009	327
30	Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial Shengxiang Ren et al. · Journal of Thoracic Oncology Open access	16 Dec 2021	326
31	Natural Killer Cells Promote Fetal Development through the Secretion of Growth-Promoting Factors Binqing Fu, Yonggang Zhou, Xiang Ni et al. · Immunity Open access	Dec 2017	320
32	The Ubiquitin Ligase Stub1 Negatively Modulates Regulatory T Cell Suppressive Activity by Promoting Degradation of the Transcription Factor Foxp3 Zuojia Chen et al. · Immunity Open access	Aug 2013	306
33	AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations Shun Lü et al. · Journal of Clinical Oncology Open access	17 May 2022	302
34	The consensus on indications, conditioning regimen, and donor selection of allogeneic hematopoietic cell transplantation for hematological diseases in China—recommendations from the Chinese Society of Hematology Lan‐Ping Xu, Chen Hu, Jing Chen et al. · Journal of Hematology & Oncology Open access	Mar 2018	300
35	Natural killer cells promote immune tolerance by regulating inflammatory T H 17 cells at the human maternal–fetal interface Binqing Fu, X.C. Li, Rui Sun et al. · Proceedings of the National Academy of Sciences Open access	27 Dec 2012	297
36	High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer Cheng Sun, Jing Xu, Qiang Huang et al. · OncoImmunology Open access	7 Dec 2016	291
37	Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma Xinan Sheng, Xieqiao Yan, Lin Wang et al. · Clinical Cancer Research Open access	27 Oct 2020	290
38	CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity Kai-Cai Liu, Ping Xu, Wei‐Fu Lv et al. · European Journal of Radiology Open access	12 Mar 2020	285
39	Genome-wide analyses of non-syndromic cleft lip with palate identify 14 novel loci and genetic heterogeneity Yanqin Yu et al. · Nature Communications Open access	24 Feb 2017	283
40	Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2) Lin Jiao, Hai‐Liang Zhang, Dandan Li et al. · Autophagy Open access	5 Oct 2017	282
41	NLRP3: A promising therapeutic target for autoimmune diseases Hui‐Hui Shen, Yuexin Yang, Xiang Ling Meng et al. · Autoimmunity Reviews	3 May 2018	278
42	Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial Zefei Jiang et al. · The Lancet Oncology	27 Apr 2019	273
43	Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats Liqin Tang, Wei Wei, Liming Chen et al. · Journal of Ethnopharmacology	5 May 2006	271
44	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China Yuankai Shi et al. · Journal of Hematology & Oncology Open access	15 Mar 2017	259
45	Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial Shun Lü et al. · The Lancet Oncology	28 Jul 2022	257
46	CD4+CD25+CD127low/− T Cells: A More Specific Treg Population in Human Peripheral Blood Ning Yu, Xiaomei Li, Xiaomei Li et al. · Inflammation	30 Jun 2012	240
47	Biological control of insects in Brazil and China: history, current programs and reasons for their successes using entomopathogenic fungi Zengzhi Li, Sérgio Batista Alves, Donald W. Roberts et al. · Biocontrol Science and Technology	14 Dec 2009	240
48	A genome-wide association study in Han Chinese identifies a susceptibility locus for primary Sjögren's syndrome at 7q11.23 Yongzhe Li et al. · Nature Genetics	6 Oct 2013	240
49	Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial Caicun Zhou, Ziping Wang, Yuping Sun et al. · The Lancet Oncology	15 Jan 2022	237
50	Development and validation of a prediction rule for estimating gastric cancer risk in the Chinese high-risk population: a nationwide multicentre study Quan-cai Cai et al. · Gut Open access	29 Mar 2019	234

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.